{
    "organizations": [],
    "uuid": "6bcfb2192ef667d4b75338d903aaace89cc67543",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-five-prime-therapeutics-to-close-b/brief-five-prime-therapeutics-to-close-bladder-cancer-cohort-of-its-phase-1-fpa144-001-trial-idUSFWN1RN0OX",
    "ord_in_thread": 0,
    "title": "BRIEF-Five Prime Therapeutics To Close Bladder Cancer Cohort Of Its Phase 1 FPA144-001 Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 10, 2018 / 4:58 PM / Updated 25 minutes ago BRIEF-Five Prime Therapeutics To Close Bladder Cancer Cohort Of Its Phase 1 FPA144-001 Trial Reuters Staff 1 Min Read \nApril 10 (Reuters) - Five Prime Therapeutics Inc: \n* TO CLOSE BLADDER CANCER COHORT OF PHASE 1 TRIAL EVALUATING BEMARITUZUMAB TREATING PATIENTS WHOSE TUMORS OVEREXPRESS FGFR2B PROTEIN \n* SAYS TO CONTINUE TREATING BLADDER CANCER PATIENTS CURRENTLY ON STUDY BUT WILL NOT ENROLL ADDITIONAL PATIENTS IN COHORT-SEC FILING Source text: ( bit.ly/2HnAIag ) Further company coverage:",
    "published": "2018-04-11T00:58:00.000+03:00",
    "crawled": "2018-04-10T20:01:02.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "prime",
        "therapeutic",
        "close",
        "bladder",
        "cancer",
        "cohort",
        "phase",
        "trial",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "five",
        "prime",
        "therapeutic",
        "inc",
        "close",
        "bladder",
        "cancer",
        "cohort",
        "phase",
        "trial",
        "evaluating",
        "bemarituzumab",
        "treating",
        "patient",
        "whose",
        "tumor",
        "overexpress",
        "fgfr2b",
        "protein",
        "say",
        "continue",
        "treating",
        "bladder",
        "cancer",
        "patient",
        "currently",
        "study",
        "enroll",
        "additional",
        "patient",
        "filing",
        "source",
        "text",
        "company",
        "coverage"
    ]
}